Notícias e Atividades da CervoMed

CervoMed é uma empresa listada sob o símbolo CRVO (US).

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da CervoMed

• John Alam, Chief Executive Officer
• Frank Zavrl, Director
• Marwan Sabbagh, Director

Recentes movimentos de executivos em CervoMed

• Mark De Rosch ingressará na Companhia como Executive Vice President, Regulatory and Government Affairs and Program Management em 1 de mai. de 2025  (Notícia publicada em 23 de abril de 2025).
• Robert Cobuzzi, Chief Operating Officer and Director, deixará a Companhia em 1 de jul. de 2025  (Notícia publicada em 23 de abril de 2025).
• Kelly Blackburn antes Senior Vice President, Clinical Development, foi promovido a Executive Vice President, Clinical Development  (Notícia publicada em 23 de abril de 2025).

Criar um alerta
para seguir os movimentos de executivos da CervoMed.

CervoMed possui 1.824 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Roche (Suíça).

Popular M&A news in Farmacêutica

• Cyclo Therapeutics adquiriu Rafael Holdings (publicado em 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Jean-Michel Demeure - Vice President, Finance Global Operations da Sanofi

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de CervoMed

• Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 | CervoMed
• CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) | CervoMed
• CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates | CervoMed
• CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies | CervoMed
• CervoMed to Present at the 8th International Lewy Body Dementia Conference | CervoMed
• CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference | CervoMed
• CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies | CervoMed
• News Releases | CervoMed
• CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CervoMed
• CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia | CervoMed
• View more press releases Close

Redes sociais sobre CervoMed

• CervoMed na Wikipedia, Google News e Yahoo Finance
• CervoMed na LinkedIn, Twitter e YouTube